Literature DB >> 24700881

Clinical and paraclinical findings in natalizumab-associated infratentorial progressive multifocal leukoencephalopathy patients.

R Hoepner1, J Ahlbrecht2, S Faissner1, R Schneider1, S Dahlhaus1, O Adams3, P Raab4, C Lukas5, A Chan1, M Stangel2, R Gold1.   

Abstract

Entities:  

Keywords:  Clinical Neurology; Multiple Sclerosis; Neurovirology

Mesh：

Substances：

Year:  2014        PMID： 24700881     DOI： 10.1136/jnnp-2014-307582

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN： 0022-3050            Impact factor:   10.154


× No keyword cloud information.
  3 in total

1.  Natalizumab-associated cerebellar PML: a case report on how to slow down IRIS.

Authors:  F Lauda; T Fangerau; K Javaheripour-Otto; E Pinkhardt; J Kassubek; H Tumani
Journal:  J Neurol       Date:  2015-02-07       Impact factor: 4.849

2.  Predictors and characteristics of seizures in survivors of progressive multifocal leukoencephalopathy.

Authors:  Dhanashri P Miskin; Susan T Herman; Long H Ngo; Igor J Koralnik
Journal:  J Neurovirol       Date:  2015-12-16       Impact factor: 2.643

Review 3.  Fingolimod for multiple sclerosis and emerging indications: appropriate patient selection, safety precautions, and special considerations.

Authors:  Ilya Ayzenberg; Robert Hoepner; Ingo Kleiter
Journal:  Ther Clin Risk Manag       Date:  2016-02-19       Impact factor: 2.423
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.